525 results on '"de Pouvourville, G"'
Search Results
102. Cost-Effectiveness Analysis of Panitumumab Plus Mfolfox6 Versus Bevacizumab Plus Mfolfox6 for First-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer
103. Effectiveness of Montelukast on Asthma Control in Infants: A Claims Data Study
104. Treatment Maintenance Duration of Dual Therapy with Metformin and Sitagliptin in Type 2 Diabetes – Real-World Data From Odyssee Study
105. Coût et impact budgétaire de l’hémodialyse à haute dose en France
106. Étude observationnelle quantifiant en vie réelle l’apport du Montelukast chez le nourrisson âgé de 6 à 24mois : méthodologie d’une étude sur l’EGB
107. PRS18 - Costs of Perennial Allergic Rhinitis And Asthma Increase with Level of Severity And Level of Disease Control
108. PHP365 - Unlocking Established Products Patient and Societal Value in Additional Indications
109. Partenariat public/privé : étude observationnelle quantifiant en vie réelle l’apport du Singulair® 4 mg chez le nourrisson âgé de 6 à 24 mois
110. The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis against venous thromboembolism following major orthopaedic surgery
111. A Cost-Utility Analysis of Ranibizumab in Age-Related Macular Degeneration Based on Real-Life Observational Data in France
112. Health State Utility Values in Advanced Non-Small Cell Lung Cancer Patients
113. Effectiveness of Montelukast on Asthma Control in Infants: Methodology of a Claims Data Study
114. P1137 Caractéristiques des patients traités par sitagliptine en vie réelle en France – Étude observationnelle Odyssée
115. P1138 Durée de maintien d’une bithérapie par metformine-sitagliptine chez les diabétiques de type 2. Étude observationnelle Odyssée
116. PCN150 Comparisons of QALYs Gained, Cost Per QALY Gained and ASMRs for 38 Anticancer Drugs in France and the UK: Vive La Difference?
117. PCV118 - A New Cost-Effectiveness Modelling Approach In Chronic Heart Failure With Reduced Ejection Fraction
118. PCV101 - The Cost-Effectiveness Of Treatment For Chronic Heart Failure: A Systematic Review
119. PMD78 - Cost-Effectiveness Analysis for The Use of The Ccp Score In The Management of Early Low Risk Prostate Cancer In The French Context
120. PMD10 Impact Analyses of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Multivessel Disease in France and Belgium
121. PMD40 Cost Effectiveness of Fractional Flow reserve Measurement in Multivessel Coronary Artery Disease in Belgium and France
122. PCN169 Differences in the Use of Innovative Anti-Cancer Drugs Among French Hospitals
123. Estimation de l’impact économique du recours à Ferinject®sur la consommation d’ASE et sur les transfusions sanguines en oncologie : analyse selon le point de vue du système de santé français
124. Étude des disparités géographiques et sectorielles dans le recours aux molécules onéreuses en oncologie
125. UT1 VALUING EQ-5D USING TIME TRADE-OFF IN FRANCE
126. PG13 PHARMACOECONOMIC ASSESSMENT OF LANREOTIDE IN THE MANAGEMENT OF POST-OPERATIVE DIGESTIVE FISTULAS
127. Optimisation de la prise en charge globale des patients atteints d’un cancer de la thyroïde
128. Étude coût-efficacité de la chimiothérapie intrapéritonéale versus une chimiothérapie palliative dans le traitement des carcinoses péritonéales d’origine colorectale
129. COST-EFFECTIVENESS OF AGGRESSIVE LDL-C LOWERING FOR ACUTE CORONARY SYNDROM PATIENTS IN FRANCE
130. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen
131. PCN6 HOSPITALIZATION COSTS FORTWO METHODS OFTSH STIMULATION DURING THE RADIOIODINE ABLATION IN THYROID CANCER PATIENTS
132. Assessment of the total cost of FNAC as a diagnostic tool in patients with thyroid nodules
133. Comparison of four strategies of follow-up in thyroid cancer patients: A cost-utility analysis
134. High dependency care unit after major cancer surgery: medical and economic impact
135. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal
136. Impact du choix d'un antiagrégant plaquettaire dans l'artériopathie oblitérante des membres inférieurs sur les pertes de chances et sur les coûts médicaux
137. Calcitonin Determination in Patients with Nodular Thyroid Disease
138. Détermination du coût du processus diagnostique de malignité par cytoponction thyroïdienne
139. Étude de la relation entre le nombre de lames reçues et le nombre de lames interprétables au cours de la cytoponction thyroïdienne
140. ES7 DIRECT MEDICAL COSTS OF STROKE ACCORDING TO HANDICAP LEVELS AFTER 12 AND 18 MONTHS
141. PEN1 DETERMINATION OF THE TOTAL COST OF DIAGNOSTIC PROCEDURE BY FINE NEEDLE ASPIRATION CYTOLOGY IN PATIENTS WITH THYROID NODULES
142. Socioeconomic and geographic determinants of survival of patients with digestive cancer in France
143. Les déterminants de l’utilisation de ressources dans 4 unités de soins palliatifs
144. P08 Impact sur les pertes de chances et les coûts du choix d’un anti-plaquettaire dans l’artériopathie des membres inférieurs
145. P9-2 - Définition pragmatique des pathologies chroniques en médecine générale
146. PCN106 - Cost-Effectiveness Analysis of Panitumumab Plus Mfolfox6 Versus Bevacizumab Plus Mfolfox6 for First-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer
147. PRS2 - Effectiveness of Montelukast on Asthma Control in Infants: A Claims Data Study
148. PDB18 - Treatment Maintenance Duration of Dual Therapy with Metformin and Sitagliptin in Type 2 Diabetes – Real-World Data From Odyssee Study
149. PCV36 CHOLESTEROL GOAL ATTAINMENT IN DYSLIPIDEMIC TREATED PATIENTS AND INCIDENCE OF CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE
150. PMC4 CAN ECONOMIC EVALUATIONS BE MADE MORE TRANSFERABLE?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.